Men at 'high' skeletal risk prior to prostate cancer hormone therapy likely to have more fractures after treatment

In what is believed to be the first study to describe the impact on men with a ‘high’ risk of bone fracture who are receiving long-term androgen deprivation therapy (ADT) for prostate cancer, new research from The Cancer Institute of New Jersey shows this population to have a higher fracture incidence following treatment completion. The findings, published in BJU International, also show that men who experienced a fracture had a 1.38-fold higher mortality risk than those who did not. Read more here.

Study mentioned: Shao YH, et al. Fracture after androgen deprivation therapy among men with a high baseline risk of skeletal complications. BJU Int. 2013 Jan 17. [Epub ahead of print] PMID: 23331464